Ask AI
ProCE Banner Activity

HERTHENA-Lung02: Phase III Trial of Patritumab Deruxtecan (HER3-DXd) vs Chemotherapy in EGFRm Advanced NSCLC After a 3rd-Generation EGFR TKI

Conference Coverage
Slideset

In the randomized phase III HERTHENA-Lung02 trial, HER3-DXd statistically significantly improved PFS but not OS while exhibiting intracranial antitumor activity vs traditional platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC previously treated with a 3rd-generation EGFR TKI. 

Released: June 03, 2025

Expiration: December 02, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar